|
1
|
SEER cancer statistics review (CSR)
1975–2010 [Internet]. June 14–2013, cited March 6th 2014].
Available from: http://seer.cancer.gov/statfacts/.
|
|
2
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
3
|
Baylin SB and Herman JG: DNA
hypermethylation in tumorigenesis: epigenetics joins genetics.
Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gama-Sosa MA, Slagel VA, Trewyn RW,
Oxenhandler R, Kuo KC, Gehrke CW and Ehrlich M: The
5-methylcytosine content of DNA from human tumors. Nucleic Acids
Res. 11:6883–6894. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herman JG, Merlo A, Mao L, et al:
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated
with aberrant DNA methylation in all common human cancers. Cancer
Res. 55:4525–4530. 1995.PubMed/NCBI
|
|
7
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pradhan S, Bacolla A, Wells RD and Roberts
RJ: Recombinant human DNA (cytosine-5) methyltransferase. I
expression, purification, and comparison of de novo and maintenance
methylation. J Biol Chem. 274:33002–33010. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okano M, Xie S and Li E: Cloning and
characterization of a family of novel mammalian DNA (cytosine-5)
methyltransferases. Nat Genet. 19:219–220. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okano M, Bell DW, Haber DA and Li E: DNA
methyltransferases Dnmt3a and Dnmt3b are essential for de novo
methylation and mammalian development. Cell. 99:247–257. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ehrlich M: DNA hypomethylation in cancer
cells. Epigenomics. 1:239–259. 2009. View Article : Google Scholar
|
|
14
|
Damiani LA, Yingling CM, Leng S, Romo PE,
Nakamura J and Belinsky SA: Carcinogen-induced gene promoter
hypermethylation is mediated by DNMT1 and causal for transformation
of immortalized bronchial epithelial cells. Cancer Res.
68:9005–9014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hollenbach PW, Nguyen AN, Brady H, et al:
A comparison of azacitidine and decitabine activities in acute
myeloid leukemia cell lines. PLoS One. 5:e90012010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cihak A: Biological effects of
5-azacytidine in eukaryotes. Oncology. 30:405–422. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsai HC, Li H, Van Neste L, et al:
Transient low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells.
Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hagemann S, Heil O, Lyko F and Brueckner
B: Azacytidine and decitabine induce gene-specific and non-random
DNA demethylation in human cancer cell lines. PLoS One.
6:e173882011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hascher A, Haase AK, Hebestreit K, et al:
DNA methyltransferase inhibition reverses epigenetically embedded
phenotypes in lung cancer preferentially affecting polycomb target
genes. Clin Cancer Res. 20:814–812. 2014. View Article : Google Scholar
|
|
20
|
Flotho C, Claus R, Batz C, et al: The DNA
methyltransferase inhibitors azacitidine, decitabine and zebularine
exert differential effects on cancer gene expression in acute
myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vidaza. EPAR - product information
(Internet). January 3–2014, cited February 6, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000978/WC500050239.pdf.
|
|
22
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Festuccia C, Gravina GL, D’Alessandro AM,
et al: Azacitidine improves antitumor effects of docetaxel and
cisplatin in aggressive prostate cancer models. Endocr Relat
Cancer. 16:401–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tikoo K, Ali IY, Gupta J and Gupta C:
5-azacytidine prevents cisplatin induced nephrotoxicity and
potentiates anticancer activity of cisplatin by involving
inhibition of metallothionein, pAKT and DNMT1 expression in
chemical induced cancer rats. Toxicol Lett. 191:158–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Francia G, Green SK, Bocci G, et al:
Down-regulation of DNA mismatch repair proteins in human and murine
tumor spheroids: implications for multicellular resistance to
alkylating agents. Mol Cancer Ther. 4:1484–1494. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Efferth T, Futscher BW and Osieka R:
5-azacytidine modulates the response of sensitive and
multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood
Cells Mol Dis. 27:637–648. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kong XB, Tong WP and Chou TC: Induction of
deoxycytidine kinase by 5-azacytidine in an HL-60 cell line
resistant to arabinosylcytosine. Mol Pharmacol. 39:250–257.
1991.PubMed/NCBI
|
|
28
|
Asano T, Nakamura K, Fujii H, et al:
Altered expression of topoisomerase IIalpha contributes to
cross-resistant to etoposide K562/MX2 cell line by aberrant
methylation. Br J Cancer. 92:1486–1492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murakami T, Li X, Gong J, Bhatia U,
Traganos F and Darzynkiewicz Z: Induction of apoptosis by
5-azacytidine: drug concentration-dependent differences in cell
cycle specificity. Cancer Res. 55:3093–3098. 1995.PubMed/NCBI
|
|
30
|
Cross M and Dexter TM: Growth factors in
development, transformation, and tumorigenesis. Cell. 64:271–280.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khan R, Schmidt-Mende J, Karimi M, et al:
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid
cells. Exp Hematol. 36:149–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abbruzzese JL and Frost P: Studies on the
mechanism of the synergistic interaction between
2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol.
30:31–36. 1992. View Article : Google Scholar
|
|
33
|
Qin T, Youssef EM, Jelinek J, Chen R, Yang
AS, Garcia-Manero G and Issa JP: Effect of AraC and decitabine in
combination in human leukemic cell lines. Clin Cancer Res.
13:4225–4232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Issa JP and Kantarjian HM: Targeting DNA
methylation. Clin Cancer Res. 15:3938–3946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene
promoter. Cancer Res. 60:6039–6044. 2000.PubMed/NCBI
|
|
36
|
Gius D, Cui H, Bradbury CM, et al:
Distinct effects on gene expression of chemical and genetic
manipulation of the cancer epigenome revealed by a multimodality
approach. Cancer Cell. 6:361–371. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gu C, Lu J, Cui T, et al: Association
between MGMT promoter methylation and non-small cell lung cancer: a
meta-analysis. PLoS One. 8:e726332013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Su Y, Xu H, Xu Y, Yu J, Xian Y and Luo Q:
Azacytidine inhibits the proliferation of human promyelocytic
leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes.
Hematology. 17:41–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dmitriev AA, Kashuba VI, Haraldson K, et
al: Genetic and epigenetic analysis of non-small cell lung cancer
with NotI-microarrays. Epigenetics. 7:502–513. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dunwell TL, Hesson LB, Pavlova T, et al:
Epigenetic analysis of childhood acute lymphoblastic leukemia.
Epigenetics. 4:185–193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Addou-Klouche L, Adelaide J, Finetti P, et
al: Loss, mutation and deregulation of L3MBTL4 in breast cancers.
Mol Cancer. 9:213PubMed/NCBI
|
|
42
|
Chen SC, Lin CY, Chen YH, et al: Aberrant
promoter methylation of EDNRB in lung cancer in Taiwan. Oncol Rep.
15:167–172. 2006.
|
|
43
|
Toyooka KO, Toyooka S, Virmani AK, et al:
Loss of expression and aberrant methylation of the CDH13
(H-cadherin) gene in breast and lung carcinomas. Cancer Res.
61:4556–4560. 2001.PubMed/NCBI
|
|
44
|
Finger EC, Turley RS, Dong M, How T,
Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung
cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Deng G, Nguyen A, Tanaka H, et al:
Regional hypermethylation and global hypomethylation are associated
with altered chromatin conformation and histone acetylation in
colorectal cancer. Int J Cancer. 118:2999–3005. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ehrlich M: DNA methylation in cancer: too
much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shang D, Liu Y, Matsui Y, Ito N, Nishiyama
H, Kamoto T and Ogawa O: Demethylating agent 5-aza-2′-deoxycytidine
enhances susceptibility of bladder transitional cell carcinoma to
cisplatin. Urology. 71:1220–1225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eklund H, Uhlin U, Farnegardh M, Logan DT
and Nordlund P: Structure and function of the radical enzyme
ribonucleotide reductase. Prog Biophys Mol Biol. 77:177–268. 2001.
View Article : Google Scholar
|
|
49
|
Lu AG, Feng H, Wang PX, Han DP, Chen XH
and Zheng MH: Emerging roles of the ribonucleotide reductase M2 in
colorectal cancer and ultraviolet-induced DNA damage repair. World
J Gastroenterol. 18:4704–4713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Morikawa T, Hino R, Uozaki H, et al:
Expression of ribonucleotide reductase M2 subunit in gastric cancer
and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Klisovic RB, Blum W, Wei X, et al: Phase I
study of GTI-2040, an antisense to ribonucleotide reductase, in
combination with high-dose cytarabine in patients with acute
myeloid leukemia. Clin Cancer Res. 14:3889–3895. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Aimiuwu J, Wang H, Chen P, et al:
RNA-dependent inhibition of ribonucleotide reductase is a major
pathway for 5-azacytidine activity in acute myeloid leukemia.
Blood. 119:5229–5238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rauscher F III and Cadman E: Biochemical
and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea
and effect on 1-beta-D-arabinofuranosylcytosine metabolism and
cytotoxicity. Cancer Res. 43:2688–2693. 1983.PubMed/NCBI
|
|
54
|
Gray SG, Baird AM, O’Kelly F, et al:
Gemcitabine reactivates epigenetically silenced genes and functions
as a DNA methyl-transferase inhibitor. Int J Mol Med. 30:1505–1511.
2012.PubMed/NCBI
|
|
55
|
Smith SL and Douglas KT: Stereoselective,
strong inhibition of ribonucleotide reductase from E. coli by
cisplatin. Biochem Biophys Res Commun. 162:715–723. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ellerhorst JA, Frost P, Abbruzzese JL,
Newman RA and Chernajovsky Y: 2′-deoxy-5-azacytidine increases
binding of cisplatin to DNA by a mechanism independent of DNA
hypo-methylation. Br J Cancer. 67:209–215. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bergman AM, Ruiz van Haperen VW, Veerman
G, Kuiper CM and Peters GJ: Synergistic interaction between
cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:521–530.
1996.PubMed/NCBI
|
